{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"84.2","value":"0"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"84.2","value":"0"},{"groupId":"OG002","lowerLimit":"0.0","upperLimit":"84.2","value":"0"},{"groupId":"OG003","lowerLimit":"0.0","upperLimit":"41.0","value":"0"},{"groupId":"OG004","lowerLimit":"2.9","upperLimit":"34.9","value":"14"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"22"}],"units":"Participants"}],"description":"ORR: Percentage of participants with an objective response (OR) per investigator. Participant was determined to have an OR if, based on 2016 IMWG uniform response criteria, \\& achieved stringent complete response (sCR), Complete response (CR), very good partial response(VGPR) \\& partial response(PR): free light chain(FLC) ratio \\& absence of clonal cells in bone marrow by immunohistochemistry(IC)/ immunofluorescence(IF). CR: negative immunofixation of serum \\& urine, disappearance of any soft tissue plasmacytomas(STP), 5% plasma cells in bone marrow. VGPR: serum \\& urine M-protein (UMP) detectable by immunofixation but not on electrophoresis/ \\>= 90% reduction in serum M-protein (SMP) level+UMP level \\<100 mg/24 hr, PR: \\>=50% reduction of SMP \\& reduction in 24-hr urinary M-protein by \\>=90%/to \\<200 mg/24 hr. If SMP \\& UMP are unmeasurable, a ≥50% decrease in the difference between involved \\& uninvolved FLC levels were required in place of the M-protein criteria.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received SEA-BCMA 100 mg as a monotherapy q2wk IV on Day 1 and 15 of each 28- day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurs first.","id":"OG000","title":"Part A: SEA-BCMA 100mg"},{"description":"Participants received SEA-BCMA 200 mg as a monotherapy q2wk IV on Day 1 and 15 of each 28- day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurs first.","id":"OG001","title":"Part A: SEA-BCMA 200mg"},{"description":"Participants received SEA-BCMA 400 mg as a monotherapy q2wk IV on Day 1 and 15 of each 28- day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurs first.","id":"OG002","title":"Part A: SEA-BCMA 400mg"},{"description":"Participants received SEA-BCMA 800 mg as a monotherapy q2wk IV on Day 1 and 15 of each 28- day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurs first.","id":"OG003","title":"Part A: SEA-BCMA 800mg"},{"description":"Participants received SEA-BCMA 1600 mg as a monotherapy q2wk IV on Day 1 and 15 of each 28- day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurs first.","id":"OG004","title":"Part A: SEA-BCMA 1600mg"}],"paramType":"NUMBER","populationDescription":"All treated participants analysis set included all treated participants who received any amount of SEA-BCMA.","reportingStatus":"POSTED","timeFrame":"From the first dose of study treatment until the first documented sCR or CR or PR or VGPR or new anti-cancer therapies or death, whichever occurred first (maximum up to 45 months)","title":"Objective Response Rate (ORR) as Per the International Myeloma Working Group (IMWG) Uniform Response Criteria: Part A","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}